Bioventix plc
(“Bioventix” or the “Company”)
Director/PDMR
Shareholding
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for application in clinical diagnostics, was notified on
19 October 2017 of the following
transactions in its ordinary shares of 5
pence each (“Ordinary Shares”):
| Director |
Position |
Ordinary Shares
sold |
Sale price per
Ordinary Share |
Ordinary Shares
held subsequently |
Percentage of
issued share capital held subsequently |
| Ian Nicholson and Persons Closely
Associated |
Non-Executive Chairman |
5,000 |
2400.75p |
18,000 |
0.4% |
| Peter Harrison and Persons Closely
Associated |
CEO |
80,000 |
2425.00p |
428,176 |
8.3% |
Notification and
public disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with them
|
Details of the person
discharging managerial responsibilities / person closely
associated |
| a) |
Names |
Ian Nicholson
(Non-Executive Chairman)
Catherine Nicholson (PCA with Ian Nicholson)
Peter Harrison (CEO) |
|
Reason for the
Notification |
| a) |
Position/status |
See 1(a) above, all are PDMR’s or
PCA’s of PDMR’s |
| b) |
Initial notification/Amendment |
Initial notification |
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix plc |
| b) |
LEI |
213800225MHX7LZQY108 |
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the Financial
instrument, type of instrument |
Ordinary shares of 5 pence
(“Ordinary Shares”) |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
In each case, sale of Ordinary
Shares |
| c) |
Price(s) and volume(s) |
Ian Nicholson:
| Price(s) |
Volume(s) |
| 2400.75p |
2,500 |
Catherine Nicholson:
| Price(s) |
Volume(s) |
| 2400.75p |
2,500 |
Peter Harrison:
| Price(s) |
Volume(s) |
| 2425.00p |
80,000 |
|
| d) |
Aggregated information: |
See 4(c) |
| e) |
Date of the transaction |
19 October
2017 |
| f) |
Place of the transaction |
London Stock Exchange,
AIM Market (XLON) |
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Stephen Norcross |
Corporate Finance
Corporate Broking |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
